1. Introduction {#s0005}
===============

Small cell lung cancer (SCLC) comprises approximately 15--18% of all lung cancers worldwide ([@bb0075]). SCLC is the most aggressive subtype of lung cancer and is characterized by rapid doubling time, high growth fraction, and early widespread metastasis ([@bb0130]). Despite high response rates to initial treatment, SCLC usually relapses and becomes refractory to treatment within one year. The median survival is 14--20 months for limited SCLC and 9--11 months for extensive SCLC ([@bb0130]). These statistics highlight the need for new tools to aid in diagnosis and prevention.

Smoking is the major risk factor for SCLC ([@bb0235], [@bb0050], [@bb0070]). However, previous studies were limited in sample size and statistical power to estimate more precise effect size of smoking on SCLC risk as well as the non-linear exposure--response relationships, which have been thoroughly explored in the previous non-small cell lung cancer (NSCLC) studies ([@bb0350]). Furthermore, smoking is also an independent risk factor for chronic obstructive pulmonary disease (COPD), which shares similar genetic and biological characteristics to lung cancer ([@bb0105], [@bb0255], [@bb0275], [@bb0340]), while concomitant COPD has not been fully examined with regard to SCLC risk ([@bb0245], [@bb0060]). Precise understanding of the association between smoking, COPD, and SCLC using a large sample size will shed light on its pathogenesis.

To address these knowledge gaps, we conducted a pooling analysis of 24 case--control studies in the International Lung Cancer Consortium (ILCCO) that in total included 4346 SCLC cases and 37,942 cancer-free controls. We examined: 1) exposure--response relationships between SCLC risk and cigarette smoking indicators, including cumulative smoking, age of initiation, and time since quitting smoking; 2) the association between physician diagnosis of COPD and SCLC risk; and 3) the interaction and mediation effects of COPD and cigarette smoking on SCLC risk.

2. Methods {#s0010}
==========

2.1. Ethics {#s0015}
-----------

Individual studies were approved by their respective ethics committees.

2.2. Study Population {#s0020}
---------------------

This pooled analysis comprised data from the ILCCO collaboration (<http://ilcco.iarc.fr>), which was established in 2004 to share data among ongoing lung cancer studies ([@bb0115]). We included 24 ILCCO studies that met the following criteria: 1) had histologically confirmed SCLC cases; 2) used a structured questionnaire to evaluate lifestyle; and 3) provided an intact study protocol. Among the 24 studies, two ([@bb0270], [@bb0085]) were cohort studies. The remaining 22 had a case--control design, ten ([@bb0210], [@bb0220], [@bb0195], [@bb0190], [@bb0145], [@bb0120], [@bb0170], [@bb0265], [@bb0355], [@bb0230]) were hospital-based, ten studies ([@bb0150], [@bb0160], [@bb0200], [@bb0280], [@bb0065], [@bb0100], [@bb0285], [@bb0040], [@bb0090], [@bb0325]) were population-based, and the other two ([@bb0335], [@bb0025]) were mixed case--control studies. The included studies were performed in North America ([@bb0085], [@bb0210], [@bb0220], [@bb0230], [@bb0280], [@bb0100], [@bb0090], [@bb0325], [@bb0335], [@bb0025]), Europe ([@bb0270], [@bb0195], [@bb0190], [@bb0170], [@bb0150], [@bb0160], [@bb0200], [@bb0065], [@bb0040], [@bb0260]), and Asia and Oceania ([@bb0190], [@bb0145], [@bb0265], [@bb0100]). Each included study was approved by the institutional review boards of the respective institutions, and each participant provided informed consent.

2.3. Case Ascertainment {#s0025}
-----------------------

Incident lung cancer cases were diagnosed pathologically and verified through review of medical records ([@bb0270], [@bb0085], [@bb0210], [@bb0220], [@bb0195], [@bb0145], [@bb0120], [@bb0170], [@bb0265], [@bb0230], [@bb0150], [@bb0160], [@bb0280], [@bb0065], [@bb0325], [@bb0335], [@bb0025], [@bb0055]), linkage to cancer registries ([@bb0190], [@bb0120], [@bb0200], [@bb0280], [@bb0065], [@bb0040], [@bb0090], [@bb0325], [@bb0025]), or linkage to mortality registries ([@bb0085], [@bb0065]). Histology information was ascertained based on the ICD for Oncology morphology codes or by individual studies. The proportion of SCLC over total lung cancers ranged from 4 to 24%. The cases that were staged as either limited stage or extensive stage were combined in the analysis.

Among the ten studies that had COPD diagnostic information (Table S1), the baseline questionnaires listed chronic emphysema, bronchitis, and/or COPD, and other lung disorders such as asthma and tuberculosis. Each subject was asked to self-report whether he/she was ever diagnosed by a physician of chronic bronchitis, emphysema, or COPD, categorized as present or absent. Subjects who had physician diagnosed chronic emphysema, bronchitis, and/or COPD were defined as having COPD. One study also validated the COPD diagnosis with pulmonary function tests ([@bb0335]).

2.4. Smoking and Other Factors {#s0030}
------------------------------

All studies collected information on lifetime history of cigarette smoking, including age of initiation of smoking, duration, intensity, and time since quitting for former smokers. To explore the non-linear association between smoking and SCLC, we generated common categorical variables related to smoking status (never smoker defined as no cumulative smoking, current smoker defined as cumulative smoking of any amount plus time since quitting smoking less than or equal to 1 year, and former smoker defined as smokers who had quit more than 1 year before diagnosis or interview), daily smoking intensity (1--9, 10--19, 20--29, 30--39, and 40 or more cigarettes/day), smoking duration (1--19, 20--29, 30--39, 40--49, and 50 or more years), and lifetime cumulative smoking (1--19, 20--39, 40--59, 60--79, and 80 or more pack-years; one pack-year being equivalent to 20 cigarettes/day smoked during 1 year). Former smokers were further categorized according to age of smoking initiation (less than 15 years, 15--20, 20--25, 25--30, or more than 30 years) and time since quitting (\< 5, 5--9, 10--19, or 20 or more years).

Other variables included in the pooled analysis were gender, age at diagnosis or interview, geographical region (North America, Europe, and Asia and Oceania), self-reported race (Asian, Black, White, Hawaiian, Hispanic, Other), family history of lung cancer (yes, no), and education level (non, elementary, vocational, postsecondary, university).

2.5. Statistical Analysis {#s0035}
-------------------------

### 2.5.1. Non-linear Exposure--Response Relationships of Smoking Behaviors on SCLC {#s0040}

The odds ratios (ORs) of SCLC and their 95% confidence intervals (95% CIs) for daily smoking intensity, duration of smoking, lifetime cumulative smoking, age of smoking initiation, and time since quitting were estimated using random-effects panel logistic regression ([@bb0035]). This multilevel model takes account of the variation among studies (panels), and study heterogeneity, during model fitting. The *ρ*, ranging from 0 to 1, represents the proportion of the total variance contributed by the panel (study)-level variance component. When *ρ* is zero, the panel-level variance component is negligible, and the estimators from the panel logistic regression are no different from that from the traditional logistic regression. Age at diagnosis and gender were adjusted for in all the regression models. Trends of SCLC risk across smoking categories were evaluated by fitting the categorical smoking variables into an ordinal regression model ([@bb0005]). To better visualize the exposure--response relationship, we plotted cumulative smoking, age of smoking initiation, and time since quitting smoking with the SCLC risks using estimates from restricted cubic spline models ([@bb0095], [@bb0030]). The non-linear association was explored by applying the likelihood test to compare the spline model to its nested linear model. Subgroup analyses were performed stratified by COPD status, gender, study area (Caucasian-dominated areas vs. non-Caucasian dominated areas), source of controls (hospital-based controls vs. population-based controls), and 1st degree family history of lung cancer (yes vs. no), and the difference of risk effects between subgroups was evaluated by including the interaction term of smoking and stratifying variable into the model.

### 2.5.2. Interaction and Mediation Analyses {#s0045}

The associations between cumulative smoking and SCLC risk were further tested in subgroups with and without preexisting COPD. We conducted the Wald test for effect modification from COPD by adding an interaction term. It is well-established that smoking is the risk to both COPD and SCLC, and COPD is a risk factor to SCLC. To explore whether the effect of smoking on the risk of SCLC is mediated through COPD, the VanderWeele\'s mediation analysis was performed ([@bb0310]). The smoking effect on SCLC was decomposed to two parts: the indirect effect which represents the effect of smoking is mediated through COPD and the direct effect which represents the effect of smoking on SCLC by pathways other than COPD. To obtain direct and indirect effects of smoking on SCLC risk, ORs for mediation analysis in the case--control setting were calculated by combining the regression of COPD and the regression of SCLC risk ([@bb0310], [@bb0315]). The proportion mediated was obtained by OR~d~ × (OR~i~ − 1) / (OR~d~ × OR~i~ − 1), where OR~d~ is the direct effect odds ratio and OR~i~ is the indirect effect odds ratio ([@bb0030]).

All tests were two-sided and evaluated using SAS software (version 9·4; SAS Institute, Cary, NC) or STATA statistical package (Version 14; Stata Corp. LP, College Station, TX, USA). A *P*-value of less than 0.05 was considered statistically significant.

3. Results {#s0060}
==========

3.1. Characteristics of Study Populations {#s0065}
-----------------------------------------

In the 24 studies with recruitment initiated since 1969, 4346 SCLC patients and 37,942 non-SCLC controls were identified (Table S1). Among ten studies with available COPD status, 1543 COPD and 14,665 non-COPD subjects were further analyzed to explore stratified and mediation effects. Demographic characteristics are summarized in [Table 1](#t0005){ref-type="table"}. SCLC patients were significantly older, male-predominant, less educated, and more commonly had a family history of lung cancer than their respective controls (*P* \< 0.01). For smoking behaviors, the proportions of current smokers/former smokers, the amount of lifetime cumulative smoking pack-years, smoking duration, and smoking intensity (cigarettes per day) in SCLCs or COPDs were significantly higher than in their respective controls, while the time since quitting smoking was significantly lower than that in controls (*P* \< 0.01). The frequency of COPD diagnosis was higher among SCLC cases (20.6%) than controls (7.6%) (*P* \< 0.001).Table 1Basic characteristics and smoking behaviors in the pooled dataset.VariableSCLC\
(n = 4346)Non-SCLC\
(n = 37,942)COPD[a](#tf0005){ref-type="table-fn"}\
(n = 503)Non-COPD[a](#tf0005){ref-type="table-fn"}\
(n = 1940)COPD[a](#tf0005){ref-type="table-fn"}\
(n = 1040)Non-COPD[a](#tf0005){ref-type="table-fn"}\
(n = 12,725)Study area Caucasian-dominated4153(95.6)503(100)1940 (100)35,944 (94.7)1040(100)12,725 (100) Non-Caucasian-dominated193(4.4)1995 (5.3)Age, mean (SD)61.2(10.5)63.9(9.4)60.6 (10.7)[b](#tf0010){ref-type="table-fn"}58.8 (12.7)[c](#tf0015){ref-type="table-fn"}61.3(10.3)58.1 (12.5)[d](#tf0020){ref-type="table-fn"}Gender (female), n (%)1371(31.6)193(38.4)601 (31.0)[b](#tf0010){ref-type="table-fn"}14,269 (37.6)[c](#tf0015){ref-type="table-fn"}373(35.9)5262 (41.4)[d](#tf0020){ref-type="table-fn"}Ethnicity (Caucasian), n (%)2310(87.1)299(59.4)1000 (51.6)[b](#tf0010){ref-type="table-fn"}23,507 (85.2)[c](#tf0015){ref-type="table-fn"}427(41.1)7442 (58.5)[d](#tf0020){ref-type="table-fn"}Education (greater than university), n (%)487(15.9)82(20.0)260 (16.8)7047 (32.1)[c](#tf0015){ref-type="table-fn"}228(27.6)3733 (43.9)[d](#tf0020){ref-type="table-fn"}First degree family history of lung cancer (≥ 1), n (%)173(15.2)25(19.5)83 (17.5)1435 (9.8)[c](#tf0015){ref-type="table-fn"}67(17.3)764 (12.2)[d](#tf0020){ref-type="table-fn"}Smoking status[b](#tf0010){ref-type="table-fn"}[c](#tf0015){ref-type="table-fn"}[d](#tf0020){ref-type="table-fn"} Never166(4.5)3(0.8)101 (7.1)13,613 (37.5)278(28.7)5075 (45.0) Former987(27.0)114(31.2)332 (23.4)13,002 (35.8)400(41.3)3875 (34.4) Current2510(68.5)249(68.0)987 (69.5)9696 (26.7)291(30.0)2332 (20.7)Smoking pack-years, mean (SD)46.8(27.9)53.7(31.5)43.3 (27.1)[b](#tf0010){ref-type="table-fn"}27.6 (24.2)[c](#tf0015){ref-type="table-fn"}32.7(27.7)24.2 (23.4)[d](#tf0020){ref-type="table-fn"}Smoking intensity (cigarettes per day), mean (SD)24.1(12.4)25.6(13.0)23.0 (12.1)[b](#tf0010){ref-type="table-fn"}18.7 (12.2)[c](#tf0015){ref-type="table-fn"}19.3(12.5)18.0 (12.4)[d](#tf0020){ref-type="table-fn"}Smoking duration (years), mean (SD)39.1(10.6)42.0(10.4)38.9 (10.4)[b](#tf0010){ref-type="table-fn"}31.2 (14.3)[c](#tf0015){ref-type="table-fn"}39.7(11.7)32.7 (14.4)[d](#tf0020){ref-type="table-fn"}Age of initiation (years), mean (SD)18.1(4.9)18.0(4.5)18.4 (4.8)[b](#tf0010){ref-type="table-fn"}18.8 (5.7)[c](#tf0015){ref-type="table-fn"}18.6(5.2)18.8 (5.4)[d](#tf0020){ref-type="table-fn"}Age of cessation (years), mean (SD)55.9(10.9)58.9(9.6)53.9 (10.7)[b](#tf0010){ref-type="table-fn"}46.0 (14.8)[c](#tf0015){ref-type="table-fn"}47.5(13.3)42.8 (14.5)[d](#tf0020){ref-type="table-fn"}Time since quitting smoking among former smokers (years), mean (SD)3.9(7.7)4.0(8.0)3.5 (7.4)[b](#tf0010){ref-type="table-fn"}13.8 (13.3)[c](#tf0015){ref-type="table-fn"}11.6(13.0)12.5 (13.1)[d](#tf0020){ref-type="table-fn"}[^2][^3][^4][^5][^6]

3.2. Association of Smoking Behaviors With SCLC Risk {#s0070}
----------------------------------------------------

Former smokers had a significantly higher risk on SCLC vs. non-smokers (OR, 6.21, 95% CI 5.21--7.41, *P* \< 0.001) while a much higher risk existed among current smokers vs non-smokers (OR, 26.72, 95% CI 22.54--31.68, *P* \< 0.001) ([Table 2](#t0010){ref-type="table"}). A statistically significant dose--response for SCLC risk was observed for all quantitative smoking variables ([Table 2](#t0010){ref-type="table"}). Cumulative smoking intensity (smoking pack-years) was associated with increased risk of SCLC vs. non-smokers in a significant dose--response manner \[ORs ranged from 4.33 for those who had pack-years \< 20 to 69.03 for those who had pack-years ≥ 80, *P* for trend (*P*~trend~) \< 0.001\]. Smoking intensity had a similar dose--response model (ORs from 4.35 ~\< 10_cigarettes-per-day~ to 34.49 ~≥ 40_cigarettes-per-day,~ *P*~trend~ \< 0.001), as well as smoking duration (ORs ranged from 2.37 ~\< 20_years~ to 48.80 ~≥ 50_years~, *P*~trend~ \< 0.001), and age of initiation (ORs from 7.09~smoking_after_30~ to 24.04~smoking_before_15~, *P*~trend~ \< 0.001). The former smokers with longer cessation showed a considerably decreased risk on SCLC risk in a dose--response trend vs. subjects who had quit smoking for less than 5 years \[OR for those who had quit for 5--9 years (OR~5--9~), 0.57, 95% CI 0.45--0.73; OR~10--19~, 0.28, 95% CI 0.23--0.36; OR ~≥ 20~, 0.11, 95% CI 0.09--0.14; *P*~trend~ \< 0.001\]. The sensitivity analysis yielded similar results with further adjustment for study areas (Caucasian-dominated areas vs. non-Caucasian-dominated areas), source of controls (hospital-based vs. population-based), and family history of lung cancer (yes vs. no) ([Table 2](#t0010){ref-type="table"}).Table 2Smoking behaviors and the risk of SCLC.Variable*N*~SCLC~/*N*~non-SCLC~Overall analysisSensitivity analysis[a](#tf0025){ref-type="table-fn"}OR (95% CI)[b](#tf0030){ref-type="table-fn"}*ZPρ*[c](#tf0035){ref-type="table-fn"}OR (95% CI)[a](#tf0025){ref-type="table-fn"}*ZPρ*[c](#tf0035){ref-type="table-fn"}Smoking status0.160.19 Never166/13,6131.00 (ref)------1.00 (ref)------ Former987/13,0026.21 (5.21,7.41)20.360.0006.13 (5.10,7.37)19.320.000 Current2510/969626.72 (22.54,31.68)37.830.00026.96 (22.57,32.21)36.320.000 Trend test48.060.00046.240.000Smoking pack-years0.160.20 Never smokers166/13,6131.00 (ref)------ \< 20462/91104.33 (3.61,5.19)15.800.0004.28 (3.51,5.21)14.420.000 20--391365/699619.19 (16.23,22.69)34.540.00018.61 (15.49,22.36)31.200.000 40--591063/353335.86 (30.12,42.71)40.170.00033.88 (27.93,41.09)35.750.000 60--79527/127555.04 (45.32,66.84)40.430.00057.91 (46.51,72.10)36.290.000 ≥ 80474/88969.03 (56.38,84.52)41.000.00073.91 (58.69,93.08)36.580.000 Trend test57.320.00051.330.000Smoking intensity (cigarettes per day)0.160.19 Never smokers166/13,6131.00 (ref)------1.00 (ref)------ \< 10246/43714.35 (3.55,5.34)14.170.0004.06 (3.26,5.05)12.510.000 10--191142/697913.70 (11.56,16.24)30.150.00013.08 (10.88,15.73)27.360.000 20--291307/667020.31 (17.14,24.08)34.680.00020.12 (16.70,24.24)31.570.000 30--39578/215429.93 (24.83,36.07)35.680.00031.67 (25.76,38.92)32.830.000 ≥ 40609/192934.49 (28.56,41.65)36.780.00035.99 (29.15,44.45)33.280.000 Trend test48.010.00043.960.000Smoking duration (years)0.120.10 Never smokers166/13,6131.00 (ref)------1.00 (ref)------ \< 20100/40002.37 (1.83,3.07)6.530.0002.52 (1.90,3.34)6.400.000 20--29543/363514.67 (12.18,17.67)28.330.00016.04 (13.05,19.72)26.360.000 30--391039/464525.54 (21.40,30.48)35.890.00028.89 (23.65,35.28)32.970.000 40--491197/425937.43 (31.16,44.95)38.760.00041.92 (34.07,51.59)35.300.000 ≥ 50561/173148.80 (39.60,60.12)36.500.00052.69 (41.73,66.54)33.300.000 Trend test46.090.00042.500.000Age of initiation (years)0.140.10 Never smokers165/13,6121.00 (ref)------1.00 (ref)------ ≥ 3080/8407.09 (5.32,9.46)13.320.0006.70 (4.92,9.13)12.050.000 25--29138/85812.57 (9.79,16.15)19.820.00012.44 (9.49,16.30)18.250.000 20--24636/359214.17 (11.71,17.15)27.220.00013.58 (11.01,16.75)24.360.000 15--191603/882615.74 (13.15,18.84)30.070.00015.48 (12.71,18.87)27.160.000 \< 15497/204924.04 (19.67,29.39)31.040.00025.30 (20.27,31.58)28.560.000 Trend test35.380.00031.960.000Time since quitting smoking among former smokers (years)0.050.04 \< 5199/7181.00 (ref)------1.00 (ref)------ 5--9158/9270.57 (0.45,0.73)4.610.0000.57 (0.45,0.72)4.630.000 10--19197/20920.28 (0.23,0.36)11.080.0000.28 (0.23,0.35)11.160.000 ≥ 20149/34930.11 (0.09,0.14)18.150.0000.11 (0.09,0.14)18.230.000 Trend test19.400.00019.490.000[^7][^8][^9]

3.3. Stratified Analyses of Smoking Behaviors on SCLC Risk {#s0075}
----------------------------------------------------------

Further, we performed the stratified analyses by COPD, gender, ethnicity, source of control, and 1st degree family history of lung cancer. All the smoking variables showed a higher effect on SCLC risk in COPD subgroup than those in non-COPD subjects with significance or borderline significance except for time since quitting smoking which was probably due to insufficient sample size (Table S2). Male smokers had a trend of stronger dose--response on SCLC risk than that in female but with a lack of statistical significance (Table S3). Smoking variables in Caucasian-dominated populations showed stronger effects on SCLC risk than those in non-Caucasian dominant populations (Table S4). No statistical significance was observed for time since quitting smoking probably due to insufficient sample size from non-Caucasian populations (Table S4). Further, stratified analyses by control type showed a trend of higher effects of smoking behaviors on SCLC risk in the studies with population-based controls than those in the studies with hospital-based controls (Table S5). Furthermore, in stratified analysis by family history of lung cancer, smoking behaviors showed a trend of, but non-significant, stronger effects in subjects with family history of lung cancer than the others (Table S6).

3.4. Non-linear Exposure--Response Relationships {#s0080}
------------------------------------------------

Further, non-linear exposure--response relationships of smoking pack-years and time since quitting smoking were explored using restricted cubic spline regression model ([Fig. 1](#f0005){ref-type="fig"}). The SCLC risk for cumulative smoking pack-years revealed an upward spline with a knot at approximately 50 pack-years (*P*~non-linear~ \< 0.001); the slope of the first segment was larger than that of the second segment ([Fig. 1](#f0005){ref-type="fig"}a). The results were consistent in the subgroup analyses stratified by COPD status ([Fig. 1](#f0005){ref-type="fig"}b for non-COPD, 1c for COPD), by gender ([Fig. 1](#f0005){ref-type="fig"}d for male, 1e for female), and study area ([Fig. 1](#f0005){ref-type="fig"}f for Caucasian-dominated areas, Fig. [1](#f0005){ref-type="fig"}g for non-Caucasian-dominated areas). In contrast, there were significantly decreasing trends between time since quitting smoking and SCLC risk among former smokers ([Fig. 1](#f0005){ref-type="fig"}h) which obtained consistent results among the subgroup analyses ([Fig. 1](#f0005){ref-type="fig"}i--m). We were not able to perform the cubic spline analysis among the former smokers in studies from non-Caucasian-dominated areas due to insufficient cases recruited.Fig. 1The dose--response relationship between smoking behaviors and the risk of SCLC. Smoking pack-years were explored on the non-linear dose--response relationship on SCLC risk among all samples (a), or stratified by COPD status (b, c), by gender (d, e), or by study areas (f, g). Time since quitting smoking was also explored by cubic spline regressions for non-linearity among all samples (h), or stratified by COPD status (i, j), by gender (k, l), or among Caucasian-dominated areas (m). Due to insufficient sample size, there was no subgroup analysis done among non-Caucasian-dominated areas. The x-axis represents the quantitative smoking information while the y-axis represents the odds in log~e~ scale.

3.5. Smoking Effect on SCLC Mediated Through COPD {#s0085}
-------------------------------------------------

Smoking behaviors were positively associated with COPD risk (Table S7). COPD status was independently associated with SCLC risk (OR, 1.86, 95% CI 1.61--2.16, *P* \< 0.001) with adjustment for age, gender, and smoking pack-years. Furthermore, to explore whether the association between smoking and SCLC risk was mediated through COPD, we performed a series of mediation analyses ([Table 3](#t0015){ref-type="table"}). A statistically significant indirect effect on SCLC risk mediated through COPD was observed for former smokers \[OR~indirect~, 1.03, *P* \< 0.001; proportion mediated (%M), 3.57%\] or current smokers (OR~indirect~, 1.06, *P* \< 0.001; %M, 5.86%), smoking pack-years (OR~indirect~ per SD, 1.03, *P* \< 0.001; %M, 4.99%), smoking intensity (OR~indirect~ per SD, 1.01, *P* \< 0.001; %M, 2.52%), smoking duration (OR~indirect~ per SD, 1.05, *P* \< 0.001; %M, 7.55%), and time since quitting smoking (OR~indirect~ per SD, 0.98, *P* = 0.005; %M, 0.70%). Overall, less than 10% of smoking\'s risk effect on SCLC was mediated through COPD [(Fig. 2)](#f0010){ref-type="fig"}.Fig. 2A diagram of mediation model.Table 3Causal mediation analysis of smoking behaviors, COPD, and the risk of SCLC.VariableOR~indirect~ (95% CI)*P*OR~direct~ (95% CI)*P*%*M*Smoking status Never vs former1.03 (1.02, 1.05)0.0005.30 (4.84, 5.81)0.0003.57 Never vs current1.06 (1.04, 1.09)0.00028.13 (23.41, 33.80)0.0005.86Smoking pack-years\
per SD (25.9) increment1.03 (1.02, 1.04)0.0002.33 (2.22, 2.44)0.0004.99Smoking intensity\
per SD (13.2) increment1.01 (1.01, 1.02)0.0001.63 (1.56, 1.71)0.0002.52Smoking duration (years)\
per SD (17.9) increment1.05 (1.03, 1.07)0.0002.58 (2.35 2.84)0.0007.55Age of initiation (years)\
per SD (5.6) increment0.99 (0.80, 1.01)0.1580.89 (0.82, 0.95)0.0017.49Time since quitting smoking among former smokers\
per SD (13.0) increment0.98 (0.97, 0.99)0.0050.26 (0.22, 0.30)0.0000.70[^10]

4. Discussion {#s0090}
=============

To our knowledge, this is the largest study investigating the relationship among multiple quantitative smoking risk factors, COPD, and risk of SCLC ([@bb0235]). The major strength of this study is its large sample size, which allowed us to have greater power to detect the exposure--response relationship of smoking behaviors, COPD, and SCLC risk in more homogeneous subgroups, and the risks of smoking mediated through COPD ([@bb0350]). Furthermore, the multi-ethnic design makes this study generalizable to the other populations ([@bb0290]). The pooling study also took advantage of the well-planned questionnaires that collected data on detailed smoking behaviors such as cumulative smoking, age since smoking initiation, and time since quitting smoking, as well as COPD status.

Our study addressed the information gap regarding the non-linear exposure-response relationships between the cigarette smoking behaviors, COPD, and risk of SCLC. SCLC risk rises sharply with the first 50 pack-years of cumulative smoking, and increases continuously with further smoking. A similar steep slope with a subsequent leveling-off of lung cancer risk for intensity of smoking and a plateauing of the SCLC risks by duration of smoking were seen in previous studies ([@bb0235], [@bb0350], [@bb0320]). Findings of very high relative risks for SCLC in smokers are in agreement with experimental findings that more extensive damage triggers the regeneration of quiescent subpopulations of cells ([@bb0175]). Those cells that are centrally located in the lungs are possibly the cellular precursors of SCLC that react to more extensive damage ([@bb0180], [@bb0185]). The leveling-off association among extremely heavy and long-term smokers might be explained by a potential saturation effect, or competing risks among heavy smokers ([@bb0320]).

Juvenile initiated cigarette smoking would have over 15-fold higher risk of SCLC in the following years compared with non-smokers. The sensitivity analysis by further adjustment for smoking duration showed a reduced magnitude of risk, which implies that the effect of smoking initiation is, to some extent, dependent on the smoking duration, while still retaining significance.

SCLC risk steadily decreased as years since smoking cessation increased, which underscores the importance of quitting smoking as early as possible. The risk remains 3.59 fold higher (95% CI 2.71--7.46, *P* \< 0.001) after 20 years\' cessation compared with never smokers. A possible mechanism for this long-term carcinogenic effect of smoking is that cigarette smoke can exert a wide range of irreversible changes in lung tissue that affect its function ([@bb0305]).

The risk of lung cancer in patients with COPD has long been established ([@bb0350], [@bb0245], [@bb0250]). However, most of the studies focused on the risk of overall lung cancer or NSCLC, while the relationship with SCLC was rarely explored or underpowered ([@bb0135]). Our analysis offers insights suggesting that 86% of increased risk of SCLC occurs in persons with COPD independent from smoking. Further, our study suggests that smoking has a higher damaging effect on lungs among subjects diagnosed of COPD than non-COPD subjects, which indicates a synergetic mechanism in lung cancer pathophysiology. This finding agrees with that of our previous study of non-small cell lung cancer ([@bb0350]). One biological explanation for this association between COPD and SCLC is that long-term pulmonary inflammation from COPD damages lung tissue and produces free radicals that may induce mutagenesis during tissue regeneration ([@bb0010]). Another potential mechanistic explanation is that impaired mucociliary function in COPD patients could hamper the removal of harmful particles ([@bb0345], [@bb0110]). Other mechanisms associated with the presence of COPD that might be associated with the inflammation and associated cytokines, development of lung cancer includes alterations to cell cycle regulation, shared genetic and epigenetic susceptibilities ([@bb0105]). Furthermore, no study has previously investigated the role of COPD as a causal mediator between smoking and SCLC. Our study demonstrates that less than 10% of the smoking risk effect on SCLC is mediated through COPD. Wang et al. reported one-third of the effect of smoking behavior on lung cancer mediated through COPD. The findings indicate a histologically-different causal role of COPD among smoking and lung cancer, which warrants further validation and experimental study ([@bb0330]).

We acknowledge some limitations in our study. First, misclassification of SCLC or COPD has to be considered since our study included diverse countries in which different diagnostic criteria may apply. A pathology comparability analysis was performed by Stang et al. in a German case series; the agreement between pathologists was 94% for SCLC, and lower in never smokers ([@bb0295]). Second, studies included were lacking information on spirometry, and underdiagnostics of COPD was thus significant among non-COPD subjects, which is about 70% of the total population ([@bb0205], [@bb0155], [@bb0020]). Due to underdiagnosed COPD patients, risks of smoking behaviors among non-COPD subgroups were, to some extent, overestimated. However, physician-diagnosed COPD is compatible with spirometry-based COPD for epidemiological studies ([@bb0300], [@bb0045], [@bb0215]). A validation assessment also confirmed that self-reported physician-diagnosed COPD correlates with high rates of true COPD in medical records ([@bb0015]). Therefore, such underdiagnosis of COPD contributes to the more conservative results for the evaluation of the risk difference between COPD and non-COPD. On the other hand, a more accurate COPD diagnostic method will result in a higher stratified effect as well as stronger statistical power. Third, medication information of COPD patients was also important to this association study. Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for worsening COPD patients ([@bb0140]), as well as a decreased risk of lung cancer in a dose--response manner ([@bb0225], [@bb0165]). Statins are also recognized as powerful anti-inflammatory agents beyond low-density lipoprotein cholesterol reduction ([@bb0240]), which have a beneficial role in COPD treatment including reduced risk of lung cancer ([@bb0125], [@bb0080]). Inclusion of the medication information in future study increases both statistical power and clinical interpretation. Besides, the source of controls, SCLC case ascertainment, COPD verification, geographical area, and recruitment period could explain partial heterogeneity. Though we detected a significant indirect effect of smoking on SCLC risk mediated by COPD, we were not able to determine the temporal relationship between COPD and SCLC in this study, and reverse causality of the pre-diagnosed stage of SCLC could thus possibly affect COPD development as well.

5. Conclusion {#s0095}
=============

This study emphasizes the non-linear association of smoking with the relative risk of SCLC. The pattern is partially supported by prior SCLC studies ([@bb0235], [@bb0320]) and hypothesis-generating experiments. Smoking also has a strong effect on COPD, and COPD is an independent risk factor on SCLC, and further, a part of smoking risk effect on SCLC is mediated through COPD. The mutually shared genetic predisposition or common mechanistic pathway among smoking behaviors, COPD and SCLC warrants investigation to facilitate early detection of SCLC.
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[^1]: The authors contributed equality to this study.

[^2]: Values are presented as n (%) for categorical data or mean(standard deviation \[SD\]) for continuous variables. The categorical variables were tested by Fisher\'s exact test and continuous variables were compared by Student *t-*test between groups/subgroups. The quantitative smoking variables were summarized among former or current smokers. SCLC: small cell lung cancer; COPD: chronic obstructive pulmonary disease.

[^3]: A subset of 10 studies that have reported COPD status in both case and control including the ReSoLuCENT study, NELCS, FHS, CAPUA, MSH-PMH, SLRI, ICARE, Mayo Clinic, MGH, and HMGU.

[^4]: *P*-value ≤ 0.01 of COPD vs. non-COPD among SCLC cases.

[^5]: *P*-value \< 0.01 of SCLC vs. non-SCLC among overall samples.

[^6]: *P*-value \< 0.01 of COPD vs. non-COPD among non-SCLC subjects.

[^7]: With further adjustment for family history of lung cancer (yes vs. no), study area (Caucasian-dominated areas vs. non-Caucasian-dominated areas), source of controls (hospital-based vs. population-based).

[^8]: Odds ratio (OR), 95% confidence interval (95% CI), Z, and *P*-values were estimated using random-effects panel logistic regression by study center with adjustment for age and gender.

[^9]: The proportion of the total variance contributed by the panel (study)-level variance component. It is ranged from 0 to 1. The closer of *ρ* to 0 represents the less heterogeneity among studies. When *ρ* is zero, the panel-level variance component is unimportant, and the panel estimator is no different from the pooled logistic estimator.

[^10]: Odds ratios (OR) were in per standard deviation (SD, among all samples) increment. The SDs of smoking pack years, smoking intensity, smoking duration, age of initiation, time since quitting smoking among former smokers were 25.9 pack-years, 13.2 cigarettes per day, 17.9 years, 5.6 years, and 13.0 years, respectively.
